|
所在平台: Coursera |
课程主页: https://www.coursera.org/learn/opioids
课程评论：没有评论
课程总结：医师/学生阿片类药物使用障碍药物辅助治疗豁免培训 本课程由弗吉尼亚大学医学院（UVASOM）和护理学院（SON）与美国成瘾精神病学会（AAAP）联合推出，旨在为希望申请豁免处方丁丙诺啡（buprenorphine）以治疗阿片类药物使用障碍的医生提供培训。课程内容共包括8个独立的学习模块，需完成8小时的学习内容。 该课程涵盖了处方临床医师在阿片类药物的急性和慢性疼痛管理中面临的新要求和指南的关键问题。参与者将进行非评分的初步评估，并完成8个录制的音频课程，提供评估问题，要求总得分达到80%以上。部分模块还包含案例研究内容。成功完成课程后，学员将获得结业证书，成功完成培训的学员在获得全职DEA执照后可申请相关豁免。 预计完成该活动的时间为9.5小时。课程于2020年3月1日上线，资助来源于SAMHSA的拨款。课程内容及发言者的观点不一定反映卫生与公共服务部的官方政策。 目标：本课程的主要目标是培训各类医疗专业人员，在安全有效的情况下，处方使用阿片类药物来治疗疼痛以及药物使用障碍，特别是通过药物辅助治疗来治疗阿片类药物使用障碍。
Part: 1
Title:Physician/Student Opiod Use Disorder MAT Waiver Training
Description:The overarching goal is to train a diverse range of healthcare professionals in the safe and effective prescribing of opioid medications for the treatment of pain, as well as the treatment of substance use disorders, particularly opioid use disorders, with medication-assisted treatments.
This online course opportunity is made possible through a joint partnership with University of Virginia School of Medicine (UVASOM) and Nursing (SON) and the American Academy of Addiction Psychiatry (AAAP), Data 2000 sponsor for this MAT waiver training. This content was created by the AAAP and has been used with permission. This course is designed to highlight important issues affecting prescribing clinicians regarding the new requirements and guidelines in opioid prescribing and management for acute and chronic pain management. The course consists of 8 individual sessions of the required 8 hours of content for physicians who wish to apply for a waiver to prescribe buprenorphine for the treatment of opioid use disorders. Sessions include a non-graded pre assessment and 8 recorded audio sessions with graded post-module questions the total of which must be completed with 80% accuracy. Some modules contain a case study component. A certification of completion will be issued for successful completion of the entire training. Students who successfully complete the course during their educational program can apply for their waiver when they obtain their full DEA license. Estimated time to complete this activity: 9.5 hours Release date: March 1, 2020 UVA Grant Dates: 09/30/2019 – 09/29/2022 Funding for this initiative was made possible by a grant from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
